Get the Stockscreener App
2.88
5.11%
0.14
After Hours:
2.88
Exagen Inc stock is traded at $2.88, with a volume of 144.19K.
It is up +5.11% in the last 24 hours and down -24.21% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$2.74
Open:
$2.79
24h Volume:
144.19K
Relative Volume:
0.31
Market Cap:
$69.27M
Revenue:
$66.58M
Net Income/Loss:
$-19.95M
P/E Ratio:
-3.1311
EPS:
-0.9198
Net Cash Flow:
$-14.27M
1W Performance:
-4.64%
1M Performance:
-24.21%
6M Performance:
-72.75%
1Y Performance:
-25.39%
1-Day Range:
$2.79
$2.96
1-Week Range:
$2.65
$3.205
52-Week Range:
$2.65
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
2.88 | 65.91M | 66.58M | -19.95M | -14.27M | -0.9198 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation pu - AD HOC NEWS
Stop Loss: Is Exagen Incs growth already priced inGap Up & High Accuracy Trade Alerts - baoquankhu1.vn
Exagen (XGN) director lists 7,500 restricted stock units in Form 3 - Stock Titan
Exagen Inc. (NASDAQ:XGN) Short Interest Update - Defense World
Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase - Stock Titan
Exagen (XGN) CEO John Aballi awarded new RSUs and options - Stock Titan
Exagen prices public offering of common stock - MSN
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat - AD HOC NEWS
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell - MarketBeat
Exagen Q4 Earnings Call Highlights - Defense World
Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK
KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria
Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart
Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus
KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat
XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha
Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN
BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India
William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka
BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India
Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus
4 Analysts Have This To Say About Exagen - Benzinga
Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India
Exagen stock maintains Outperform rating at William Blair - Investing.com Australia
Exagen Q4 2025 Earnings Call Transcript - MarketBeat
XGN: FY 2025 revenue rose 20% with improved margins and expanded AVISE diagnostics platform - TradingView
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com India
Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart
Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus
XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus
Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations By Investing.com - Investing.com South Africa
Exagen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Exagen 2025 10-K: Revenue $66.6M; net loss $(19.95)M - TradingView
XGN: Record 2025 revenue of $66.6M (+19.7%) with net loss of $20.0M; strong AVISE® CTD growth - TradingView
Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative
Exagen reports record 2025 revenue $66.6M, ASP rises to $441; Q4 revenue $16.6M - TradingView
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results - The Manila Times
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):